OPKO Health Stock Forecast, Price & News

-0.12 (-3.13 %)
(As of 06/23/2021 01:39 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume66,438 shs
Average Volume6.19 million shs
Market Capitalization$2.49 billion
P/E Ratio19.58
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive OPK News and Ratings via Email

Sign-up to receive the latest news and ratings for OPKO Health and its competitors with MarketBeat's FREE daily newsletter.

OPKO Health logo

About OPKO Health

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.78 out of 5 stars

Medical Sector

214th out of 2,105 stocks

Pharmaceutical Preparations Industry

103rd out of 832 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

OPKO Health (NASDAQ:OPK) Frequently Asked Questions

Is OPKO Health a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPKO Health stock.
View analyst ratings for OPKO Health
or view top-rated stocks.

What stocks does MarketBeat like better than OPKO Health?

Wall Street analysts have given OPKO Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OPKO Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting OPKO Health?

OPKO Health saw a drop in short interest during the month of May. As of May 28th, there was short interest totaling 57,960,000 shares, a drop of 27.2% from the May 13th total of 79,650,000 shares. Based on an average daily trading volume, of 4,740,000 shares, the days-to-cover ratio is currently 12.2 days. Approximately 14.4% of the shares of the stock are sold short.
View OPKO Health's Short Interest

When is OPKO Health's next earnings date?

OPKO Health is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for OPKO Health

How were OPKO Health's earnings last quarter?

OPKO Health, Inc. (NASDAQ:OPK) posted its earnings results on Wednesday, April, 28th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.05. The biotechnology company earned $545.20 million during the quarter, compared to the consensus estimate of $503 million. OPKO Health had a net margin of 6.83% and a trailing twelve-month return on equity of 7.34%.
View OPKO Health's earnings history

How has OPKO Health's stock been impacted by COVID-19?

OPKO Health's stock was trading at $1.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OPK stock has increased by 120.7% and is now trading at $3.73.
View which stocks have been most impacted by COVID-19

What price target have analysts set for OPK?

2 equities research analysts have issued 1 year price objectives for OPKO Health's shares. Their forecasts range from $7.00 to $10.00. On average, they expect OPKO Health's share price to reach $8.33 in the next year. This suggests a possible upside of 123.4% from the stock's current price.
View analysts' price targets for OPKO Health
or view top-rated stocks among Wall Street analysts.

Who are OPKO Health's key executives?

OPKO Health's management team includes the following people:
  • Dr. Phillip Frost, Chairman & CEO (Age 85, Pay $971.2k)
  • Dr. Jane H. Hsiao Ph.D., MBA, Vice Chairman & Chief Technical Officer (Age 74, Pay $911.2k)
  • Mr. Adam E. Logal, Sr. VP & CFO (Age 43, Pay $1.11M)
  • Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 61, Pay $821.2k)
  • Dr. Jon R. Cohen, Sr. VP & Director (Age 66, Pay $1.74M)
  • Dr. Arie Gutman, Pres of API (Age 67)
  • Mr. James DeMarco, Sr. VP of Pharmaceutical Sales
  • Dr. Akhtar Ashfaq, Sr. VP of Clinical R&D and Medical Affairs
  • Ms. Jane Pine Wood J.D., Esq., Chief Legal Officer of Bio-Reference Laboratories (Age 58)
  • Dr. David Okrongly Ph.D., Pres of OPKO Diagnostics (Age 62)

What is Philip Frost's approval rating as OPKO Health's CEO?

21 employees have rated OPKO Health CEO Philip Frost on Philip Frost has an approval rating of 16% among OPKO Health's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of OPKO Health's key competitors?

What other stocks do shareholders of OPKO Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T).

What is OPKO Health's stock symbol?

OPKO Health trades on the NASDAQ under the ticker symbol "OPK."

Who are OPKO Health's major shareholders?

OPKO Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.78%), Oracle Investment Management Inc. (1.91%), Geode Capital Management LLC (1.12%), Dimensional Fund Advisors LP (1.10%), Northern Trust Corp (0.87%) and D. E. Shaw & Co. Inc. (0.53%). Company insiders that own OPKO Health stock include Anthony J Japour, Jane Ph D Hsiao, Jon R Cohen, Phillip Md Et Al Frost, Richard C Pfenniger Jr and Steven D Rubin.
View institutional ownership trends for OPKO Health

Which major investors are selling OPKO Health stock?

OPK stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Credit Suisse AG, Oracle Investment Management Inc., Prudential Financial Inc., AQR Capital Management LLC, Morgan Stanley, Tudor Investment Corp Et Al, and UBS Asset Management Americas Inc..
View insider buying and selling activity for OPKO Health
or view top insider-selling stocks.

Which major investors are buying OPKO Health stock?

OPK stock was bought by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Dimensional Fund Advisors LP, Hennion & Walsh Asset Management Inc., BlackRock Inc., Citigroup Inc., Altshuler Shaham Ltd, UBS Group AG, and Geode Capital Management LLC. Company insiders that have bought OPKO Health stock in the last two years include Anthony J Japour, Jane Ph D Hsiao, Jon R Cohen, Phillip Md Et Al Frost, Richard C Pfenniger Jr, and Steven D Rubin.
View insider buying and selling activity for OPKO Health
or or view top insider-buying stocks.

How do I buy shares of OPKO Health?

Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OPKO Health's stock price today?

One share of OPK stock can currently be purchased for approximately $3.73.

How much money does OPKO Health make?

OPKO Health has a market capitalization of $2.50 billion and generates $1.44 billion in revenue each year. The biotechnology company earns $30.59 million in net income (profit) each year or $0.05 on an earnings per share basis.

How many employees does OPKO Health have?

OPKO Health employs 5,269 workers across the globe.

What is OPKO Health's official website?

The official website for OPKO Health is

Where are OPKO Health's headquarters?

OPKO Health is headquartered at 4400 BISCAYNE BLVD., MIAMI FL, 33137.

How can I contact OPKO Health?

OPKO Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]

This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.